Page 69 - CIBERES2016-ENG

Most relevant scientific articles
• Kalograiaki I., Euba B., Proverbio D., Campanero-Rhodes M.A., Aastrup T., Garmendia J. et al. Combined Bacteria Microarray and Quartz Crystal Microbalance Approach for Exploring Glycosignatures of Nontypeable Haemophilus influenzae and Recognition by Host Lectins. Analytical Chemistry. 2016;88(11):5950-5957.
• Blazquez B., Fresco-Taboada A., Iglesias-Bexiga M., Menendez M., Garcia P. PL3 amidase, a tailor- made lysin constructed by domain shuffling with potent killing activity against pneumococci and related species. Frontiers in Microbiology. 2016;7(JUL).
• Kong N, Xie S, Zhou J, Menéndez M, Solís D, Park J et al. Catalyst-Free Cycloaddition Reaction for the Synthesis of Glyconanoparticles.ACS applied materials & interfaces. 2016;.
• Ruiz-Masó JA, Bordanaba-Ruiseco L, Sanz M, Menéndez M, Del Solar G. Metal-Induced Stabilization and Activation of Plasmid Replication Initiator RepB.Frontiers in molecular biosciences. 2016; 3:56.
Highlights
• The study of glycosylation patterns of Klebsiella pneumoniae clinical isolates exhibiting or not hypermucoviscous phenotypes has been initiated using lectins with different carbohydrate-binding specificities, in collaboration with Dr. C. Ardanuy (Group 19). The role of Haemophilus influenzae lipopolysaccharide as possible ligand for Viscum album and Ricinus communis agglutinins was also examined in collaboration with Dr. J. Garmendia (Group 19).
• Applicability of bacteria micorrays was extended to several streptococci, and behaviour of unfixed and fixed bacteria was compared. A comparative analysis of the binding of lectins of the innate immune system to the major respiratory pathogens has been started.
• A microarray study of the role diiA and pspA pneumococcal proteins in lactoferrin binding was initiated using diiA, pspA, or diiA plus pspA TIGR4 defective mutants, in collaboration with Dr. J.E. Yuste (Group 2).
• We have designed, produced, and tested in vitro and in vivo the PL3 chimera, the most potent amidase killing S. pneumoniae so far described. Several chimeric lysins with broader spectrum of susceptible bacteria have been also cloned and purified; testing of their bacteriolytic activities is in progress in collaboration with Dr. P. García (Group 2).
• We accomplished the structural and functional characterization of CW_7 cell-wall binding repeats, present in more than 300 proteins involved in cell wall synthesis or hydrolysis, several of them with proved antimicrobial activity.
• New compounds with bacteriostatic and/or bactericide activity against several respiratory pathogens were identified by screening of a non-commercial, chemical library. In vitro characterization of their activities has been initiated, in collaboration with Group 2.
ACTIVE PROJECTS
• 2011-2016. DYNANO (EU; FP7-ITN-GA:289003)
• 2012-2016. GLYCOPHARM (UE; FP7-PEOPLE-2012-ITN-317297)
• 2013-2016. Exploring exogenous and endogenous factors as tools for the control of infectious and
immune processes (BFU2012-36825)
• 2016-2018. Search and development of new preventive and therapeutic approaches for fighting
infections caused by Streptococcus pneumoniae (BFU2015-70052-R)
RES
research groups 69